Informazioni su Oculis Holding AG
Dati di solvibilità
Valutazione della solvibilità con semaforo come indicatore del rischio e ulteriori informazioni sull'azienda.Per saperne di più
Informazioni economiche
Informazione completa sulla situazione economica di un'azienda.Per saperne di più
Tempestività di pagamento
Valutazione della tempestività di pagamento sulla base di fatture passate.Per saperne di più
Estratto dell'ufficio di esecuzione
Panoramica delle procedimenti esecutivi attuali e passati.Per saperne di più
Informazioni sulle partecipazioni
Scoprite in quali società nazionali e internazionali la società per azioni che vi interessa detiene ancora delle partecipazioni.Per saperne di più
Dossier aziendale come PDF
Informazioni di contatto, cambiamenti nella azienda, cifre sul fatturato e sui dipendenti, gestione, proprietà, struttura azionaria e altri dati aziendali.Richiedere il fascicolo aziendale
Su Oculis Holding AG
- Oculis Holding AG opera nel settore «Esercizio delle altre istituzione finanziario» ed è attualmente attiva. La sede è a Zug.
- Oculis Holding AG ha 12 persone nella dirigenza.
- L’ultima modifica nel registro di commercio è stata effetuata il 11.07.2025. Nella rubrica “Comunicati” troverà tutte le modifiche.
- L’azienda è iscritta nel Registro di commercio ZG con l’IDI CHE-396.695.611.
- Allo stesso indirizzo sono iscritte 118 altre aziende attive. Queste includono: Adorea Holding AG, Alchemy Pay AG, Aleph Zero Stiftung.
Dirigenza (12)
i più recenti membri del consiglio d'amministrazione
Arshad M. Khanani,
Robert K. Warner,
Anthony Adam Rosenberg,
Christina Maria Ackermann,
Geraldine O'Keeffe
i più recenti aventi diritto di firma
Maria Saiz Garcia,
Anthony Adam Rosenberg,
Christina Maria Ackermann,
Geraldine O'Keeffe,
Lionel Marie Sadi Carnot
Amministrazione
Informazioni sul registro di commercio
Iscrizione al Registro di commercio
31.10.2022
Forma giuridica
Società anonima
Domicilio legale dell'azienda
Zug
Ufficio del registro di commercio
ZG
Numero di iscrizione nel registro di commercio
CH-170.3.047.845-1
IDI/IVA
CHE-396.695.611
Ramo economico
Esercizio delle altre istituzione finanziario
Scopo (Lingua originale)
Die Gesellschaft bezweckt den Erwerb, das Halten, die Verwaltung und die Veräusserung von Beteiligungen an Gesellschaften aller Art in der Schweiz und im Ausland, insbesondere in den Bereichen Forschung und Entwicklung auf dem Gebiet von pharmazeutischen Produkten, einschliesslich biologischen und biotechnologischen Produkten, sowie die Herstellung und Kommerzialisierung derartiger Produkte. Die Gesellschaft kann Patente, Urheberrechte, Marken und andere Immaterialgüterrechte sowie Lizenzen jeder Art erwerben, halten und veräussern. Die Gesellschaft kann alle kommerziellen, finanziellen und anderen Tätigkeiten ausüben, welche mit dem Zweck der Gesellschaft direkt oder indirekt im Zusammenhang stehen. Die Gesellschaft kann Beteiligungen an anderen Unternehmen im In- und Ausland erwerben, halten und veräussern. Sie kann Zweigniederlassungen und Tochtergesellschaften im In- und Ausland errichten. Die Gesellschaft kann Grundstücke erwerben, verwalten und veräussern sowie Vermögensanlagen anderer Art tätigen.
Revisori dei conti
Collegio dei revisori attuale (1)
Nome | Luogo | Dal | Al | |
---|---|---|---|---|
PricewaterhouseCoopers SA | Lausanne | 06.03.2023 |
Altri nomi dell'azienda
Nomi dell'azienda precedenti e tradotti
- Oculis Holding Ltd
- Oculis Holding SA
Succursale (0)
Assetto proprietario
Partecipazioni
Ultimi comunicati FUSC: Oculis Holding AG
Le comunicazioni aggiornate del foglio ufficiale svizzero di commercio (FUSC) sono disponibili solo nella lingua originale dell’Ufficio del Registro di commercio. Visualizza tutti comunicati
Numero di pubblicazione: HR02-1006382167, Ufficio del registro di commercio Zugo, (170)
Oculis Holding AG, in Zug, CHE-396.695.611, Aktiengesellschaft (SHAB Nr. 117 vom 20.06.2025, Publ. 1006361973).
Eingetragene Personen neu oder mutierend:
PricewaterhouseCoopers SA (CHE-497.306.752), in Lausanne, Revisionsstelle [bisher: in Pully].
Numero di pubblicazione: HR02-1006361973, Ufficio del registro di commercio Zugo, (170)
Oculis Holding AG, in Zug, CHE-396.695.611, Aktiengesellschaft (SHAB Nr. 78 vom 24.04.2025, Publ. 1006315637).
Statutenänderung:
04.06.2025. Die Generalversammlung hat das Kapitalband gemäss näherer Umschreibung in den Statuten angepasst. [bisher: Die Generalversammlung hat das Kapitalband gemäss näherer Umschreibung in den Statuten angepasst.]. Die Generalversammlung hat mit Beschluss vom 04.06.2025 die Statutenbestimmung über die weitere bedingte Kapitalerhöhung vom 29.05.2024 geändert. [bisher: Die Generalversammlung hat mit Beschluss vom 29.05.2024 die Statutenbestimmung über das weitere bedingte Kapital vom 02.03.2023 geändert.]
Numero di pubblicazione: UP04-0000007143, Ufficio del registro di commercio Zurigo
"Category: Notifications issued to company members/nSub-category: Invitation to the General Meeting/nPublication date: SHAB 12.05.2025/nPublicly viewable until: 12.05.2026/nPublication number: UP04-0000007143/nPublishing entity/nVISCHER AG - MST, Aeschenvorstadt 4.
4010 Basel/nInvitation to the ordinary general meeting Oculis/nHolding AG/nOrganisation concerned:
/nOculis Holding AG/nCHE-396.695.611/nBahnhofstrasse 20/n6300 Zug/nGeneral meeting details:/n04.06.2025, 15.00 Uhr, Ochsen-Zug, Kolinplatz 11, CH-6300 Zug.
Switzerland/nInvitation/Agenda:
/nPlease refer to the attached PDF ""Invitation to the 2025 Annual General Meeting of/nShareholders"" of Oculis Holding AG. This document contains the agenda items, the/nproposals of the Board of Directors and additional information./nTo the Shareholders of Oculis Holding AG, in Zug.
SWITZERLAND/nInvitation to the 2025 Annual General Meeting of Shareholders/nDate:
4 June 2025.
at 3:
00 p.m. CEST / 9:00 a.m.
EDT/nPlace:
Ochsen-Zug, Kolinplatz 11, CH-6300 Zug.
Switzerland/nAGENDA ITEMS AND PROPOSALS OF THE BOARD OF DIRECTORS:
/n1. APPROVAL OF THE 2024 ANNUAL REPORT INCLUDING THE 2024 ANNUAL/n (STATUTORY) FINANCIAL STATEMENTS AND THE 2024 CONSOLIDATED/n FINANCIAL STATEMENTS/n The Board proposes the approval of the annual report including the annual financial/n statements for the business year 2024 and the consolidated financial statements for/n the business year 2024./n Explanation: Pursuant to Swiss law (art. 698 para. 2 no. 3 and 4 of the Swiss Code/n of Obligations (the ""CO"")) and our articles of association, the general meeting of the/n shareholders (the ""General Meeting"") resolves on the approval of the statutory/n financial statements and the consolidated financial statements. In its reports to the/n General Meeting, the Company's auditors, PricewaterhouseCoopers SA,/n recommend without qualification the approval of the Company's annual financial/n statements and consolidated financial statements. The 2024 Annual Report is/n available for download at https://investors.oculis.com/events-presentations./n 2. ALLOCATION OF BALANCE SHEET RESULTS 2024/n The Board proposes that the balance sheet loss of CHF 46'577'000 be carried/n forward to the new accounts./n Net loss for the business year 2024 CHF 5'179'000/n Accumulated loss brought forward CHF 46'577'000/n Explanation: Pursuant to Swiss law (art. 698 para. 2 no. 4 CO) and our articles of/n association, the General Meeting resolves on the allocation of the balance sheet/n results./n3. DISCHARGE TO THE MEMBERS OF THE BOARD OF DIRECTORS AND THE/n EXECUTIVE COMMITTEE/n The Board proposes that a full discharge be granted to all members of the Board of/n Directors and the Executive Committee for their activities in 2024./n Explanation: Pursuant to Swiss law (art. 698 para. 2 no. 7 CO) and our articles of/n association, the General Meeting resolves on the discharge to the members of the/n Board of Directors and the Executive Committee./n4. RE-ELECTION OF THE CHAIRPERSON AND THE OTHER MEMBERS OF THE/n BOARD OF DIRECTORS/n The term of office of the Chairperson and all members of the Board of Directors/n expires at the end of the 2025 Annual General Meeting. The Board of Directors/n proposes the re-election of the current members of the Board of Directors, including/n the Chairperson, each until the end of the 2026 Annual General Meeting./n4.1 Re-election of Anthony Rosenberg as Member and Chairperson of the Board/n of Directors/n 4.2. Re-election of Christina Ackermann/n 4.3. Re-election of Lionel Carnot/n 4.4. Re-election of Arshad M. Khanani/n 4.5. Re-election of Martijn Kleijwegt/n 4.6. Re-election of Geraldine O'Keeffe/n 4.7. Re-election of Riad Sherif/n 4.8. Re-election of Robert K.
Warner/n Explanation:
Pursuant to Swiss law (art. 698 para. 2 no. 2 and para. 3 no. 1 CO)/n and our articles of association, the General Meeting elects the Chairperson and the/n other members of the Board of Directors. The elections will be held on an individual/n basis./n5. RE-ELECTION OF THE MEMBERS OF THE COMPENSATION COMMITTEE/n The Board of Directors proposes the re-election of Christina Ackermann, Lionel/n Carnot and Robert K. Warner as members of the Compensation Committee, each/n until the end of the 2026 Annual General Meeting./n 5.1. Re-election of Christina Ackermann/n 5.2. Re-election of Lionel Carnot/n 5.3. Re-election of Robert K.
Warner/n Explanation:
Pursuant to Swiss law (art. 698 para. 3 no. 2 CO) and our articles of/n association, the General Meeting elects the members of the Compensation/n Committee. The elections will be held on an individual basis. The Board of Directors/n intends to re-appoint Christina Ackermann, subject to her re-election, as chairperson/n of the Compensation Committee./n6. RE-ELECTION OF THE AUDITORS/n The Board of Directors proposes to re-elect PricewaterhouseCoopers SA, in Pully,/n Switzerland, as the Company's statutory auditors for a term of office of one year./n Explanation: Pursuant to Swiss law (art. 698 para. 2 no. 2 CO) and our articles of/n association, the General Meeting elects the auditors. PricewaterhouseCoopers SA/n confirmed its independence required for this mandate./n7. RE-ELECTION OF THE INDEPENDENT PROXY/n The Board of Directors proposes to re-elect PST Legal AG, in Zug, Switzerland, as/n the Company's independent proxy until the end of the 2026 Annual General Meeting./n Explanation: Pursuant to Swiss law (art. 698 para. 3 no. 3 CO) and our articles of/n association, the General Meeting elects the independent proxy. PST Legal AG/n confirmed its independence required for this mandate./n8. COMPENSATION FOR THE NON-EXECUTIVE MEMBERS OF THE BOARD OF/n DIRECTORS/n8.1 Vote on Total Fixed (Non-Performance-Related) Compensation for Non-/n Executive Members of the Board of Directors until the end of the Company's/n 2026 Annual General Meeting/n The Board of Directors proposes the approval of a total maximum amount of fixed/n (non-performance-related) compensation for eight non-executive members of the/n Board of Directors for the period from the Company's 2025 Annual General Meeting/n to the Company's 2026 Annual General Meeting of USD 572'000./n 8.2. Vote on Equity or Equity Based Compensation for Non-Executive/n Members of the Board of Directors until the end of the Company's 2026/n Annual General Meeting/n The Board of Directors proposes the approval of the grant of options with share/n equivalent, shares or equity linked instruments for eight non-executive/n members of the Board of Directors for the period until the end of the Company's/n 2026 Annual General Meeting, with a then current maximum value of all equity/n or equity linked instruments of USD 2'150'000 (excluding employer social/n security and pension contributions)./n Explanation (agenda items 8.1 and 8.2): Pursuant to Swiss law (art. 698/n para. 3 no. 4 CO) and our articles of association, the General Meeting resolves/n on the approval of the maximum compensation of the Board of Directors/n broken down into fixed (non-performance related) compensation and the/n equity or equity-based compensation. Further information on the Company's/n compensation principles for the Board of Directors can be found in our articles/n of association and in the 2024 Compensation Report.
which is available for/n download at https:
//investors.oculis.com/events-presentations./n9. COMPENSATION FOR THE MEMBERS OF THE EXECUTIVE COMMITTEE/n 9.1. Vote on Fixed (Non-Performance-Related) Compensation for Members of/n the Executive Committee payable in 2026/n The Board of Directors proposes to approve a total maximum amount of fixed/n (non-performance-related) compensation for three members of the Executive/n Committee for the calendar year 2026 and payable in 2026 of USD 2'478'240./n 9.2. Vote on variable Compensation for Members of the Executive Committee/n payable in 2026/n The Board of Directors proposes to approve "
Lista dei risultati
Qui trovate un link della dirigenza ad una lista di persone con lo stesso nome, che sono registrate nel registro di commercio.